Key result
Sodium zirconium cyclosilicate and patiromer are new oral potassium binders that have been tested in phase 3 short-term studies for the treatment of hyperkalemia.
Why the study?
Do novel oral potassium binders (sodium zirconium cyclosilicate and patiromer) effectively treat hyperkalemia?
Do novel oral potassium binders (sodium zirconium cyclosilicate and patiromer) effectively treat hyperkalemia?
Sodium zirconium cyclosilicate and patiromer represent novel oral potassium binder options for the long-term treatment of hyperkalemia.
These binders may enable continued RAAS inhibitor therapy in hyperkalemia; extends short-term phase 3 data but requires long-term outcome trials.
Hyperkalemia is a common clinical problem. While several options are available to treat acute hyperkalemia, there are few options for long-term treatment. The use of oral potassium binders might be such an option. Sodium zirconium cyclosilicate and patiromer are two new oral potassium binders awaiting approval. The efficacy of these novel potassium-lowering agents were tested in several phase 3 short-term studies published in late 2014.
No takes yet. Share an insight, caveat, or question.
Roland Schmitt (2015) conducted a review in Hyperkalemia. Sodium zirconium cyclosilicate and patiromer was evaluated. Sodium zirconium cyclosilicate and patiromer are new oral potassium binders that have been tested in phase 3 short-term studies for the treatment of hyperkalemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: